← All trials
NCT06038617
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Sep 15, 2023
- Last posted
- Nov 2, 2023
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- Duke UniversityOverall official - principal investigator
- Kaiser PermanenteCollaborator
- Columbia UniversityCollaborator
- University of CincinnatiCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.